CW April 2003
Volume 12Issue Number 4 April 2003 ISSN 10593802 Patients Most Likely to Benefit From Erythropoietic Therapy Often UntreatedWhile at least 40% of chemotherapy patients with hemoglobin at levels below those recommended in guidelines for treatment with erythropoietic agents (10 g/dl) are not treated, recent quality of life data suggest that patients with hemoglobin in the range of 10-12 g/dL benefit most from such therapy.
Go to Previous Page Go to Next Page Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW April 2003Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
